Recent clinical trial results and the decision by the US Food and Drug Administration to issue an emergency use authorisation for remdesivir have highlighted the urgency of this work and the importance of planning for access to remdesivir globally.
Remdesivir manufacturing relies on "scarce" raw materials that command their own "lengthy" production timelines, Gilead has said.
With several countries across the globe reeling from the coronavirus pandemic, interest in remdesivir has been high as there are now no approved treatments or vaccines for Covid-19, the respiratory illness caused by the new coronavirus.
"While remdesivir is an example of the sort of innovative antiviral medicines coming from Gilead's pipeline, which has created a portfolio of HIV and hepatitis C drugs that support a wide moat, we don't think the drug has yet demonstrated that it will have a large and sustained impact on Gilead's future cash flows", Andersen said.
Buffett's Berkshire posts record net loss on coronavirus, operating profit rises
Moreover, Berkshire is already heavily invested in some of those industries, such as energy, airlines and financial services, according to Mr.
Was Kim Jong Un Actually Seen In Public After His Mysterious Absence?
Trump said Saturday he was pleased about Kim's reappearance and that the North Korean leader is apparently healthy. There were questions about his health after he missed the anniversary of the birth of Kim Il Sung on 15 April.
Warren Buffett's Berkshire Hathaway Posts Nearly $50 Billion Loss Amid Coronavirus Pandemic
Like many other events, the annual pilgrimage had to go online for the first time due to the coronavirus pandemic. The billionaire investor said Berkshire Hathaway completely exited its stakes in the four major U.S. airlines.
By the end of next month, Gilead said it expects to have manufactured enough of the drug to treat more than 140,000 patients, and it plans to donate that supply to hospitals.
'There has been no other time like this in the history of the planet, ' O'Day said. He went as far as to say that remdesivir will be "the standard of care" for COVID-19 patients.
The US recently approved Remdesivir, a key antiviral drug from Gilead Sciences, for emergency use on COVID-19 patients.
Data from a trial run by Gilead, also unveiled on Wednesday, showed similar clinical improvements in patients with severe symptoms of COVID-19, regardless of whether they received five or ten days of treatment. Remdesivir, a direct acting antiviral drug that inhibits viral RNA synthesis, received emergency USA approval on May 1. Gilead has already licensed several other medicines to the group, MPP's website shows.